Treatment of schizoaffective disorder - A challenge for evidence-based psychiatry

Acta Psychiatrica Scandinavica

Volumn 121, Issue 1, 2010, Pages 22-32

  Jager M ^a   Becker, T ^a   Weinmann, S ^b   Frasch, K ^a  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antipsychotics; Classification; Mood stabilizers; Schizophrenia; Treatment

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; PSYCHIATRIC STATUS RATING SCALES; PSYCHIATRY; PSYCHOMETRICS; PSYCHOTIC DISORDERS;

EID: 72249105769     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2009.01424.x     Document Type: Article

References (91)

1. Kraepelin E. Psychiatrie, 6th edn. Leipzig : Barth, 1899.
2. Langfeld G. The schizophreniform states. Copenhagen : Munskgaard, 1939.
3. Leonhard K. Die Aufteilung der endoge nen Psychosen und ihre differenzierte Ätiologie. Berlin : Akademie, 1957.
4. Strömgren E. The development of the concept of reactive psychoses. Psychopathology 1987 20 : 62 67.
5. Kasanin J. The acute schizoaffective psychoses. Am J Psychiatry 1933 13 : 97 126.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition text revision (DSM-IV-TR Washington, DC : APA, 2000.
7. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva : WHO, 1993.
8. Spitzer RL, Endicott J, Robins E. Clinical criteria for psychiatric diagnosis and DSM-III. Am J Psychiatry 1975 132 : 1187 1192.
9. Lange W, Munk-Jorgensen P, Bertelsen A et al. Comparison of psychiatric ICD-10 diagnoses in Denmark and Germany. Psychopathology 2002 35 : 36 47.
10. Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 2009 60 : 210 216.
11. Marneros A, Tsuang MT (eds). Schizoaffective psychoses. Berlin : Springer, 1986.
12. Marneros A, Goodwin F (eds). Bipolar disorders. Mixed states, rapid cycling and atypical forms. Cambridge : Cambridge University Press, 2005.
13. Marneros A, Akiskal HG (eds). Overlap of affective and schizophrenic spectra. Cambridge : Cambridge University Press, 2007.
14. Marneros A. Do schizoaffective disorders exist at all? Acta Psychiatr Scand 2007 115 : 162.
15. Vollmer-Larsen A, Jacobsen TB, Hemmingsen R, Parnas J. Schizoaffective disorder - the reliability of its clinical diagnostic use. Acta Psychiatr Scand 2006 113 : 402 407.
16. Maier W. Do schizoaffective disorders exist at all? Acta Psychiatr Scand 2006 13 : 369 371.
17. Ghaemi SN. The case for, and against, evidence-based psychiatry. Acta Psychiatr Scand 2009 119 : 249 251.
18. Keck P Jr., Reeves KR, Harrigan EP, and the Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001 21 : 27 35.
19. Tohen M, Zhang F, Keck JRPE et al. Olanzapine versus haloperidol in schizoaffective disorder bipolar type. J Affect Disord 2001 67 : 133 140.
20. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia. Arch Gen Psychiatry 1998 55 : 250 258.
21. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley JRCM. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Br J Psychiatry 1999 174 : 15 22.
22. Janicak PG, Keck PE, Davis JM et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001 21 : 360 368.
23. Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 1984 19 : 445 449.
24. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002 63 : 1156 1163.
25. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA. Efficacy and safety of long-acting risperidon in stable patients with schizoaffective disorders. J Affect Disord 2004 83 : 263 275. (Pubitemid 39536205)
26. Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-months, multicenter, open study. J Clin Psychiatry 2001 10 : 818 825. (Pubitemid 33104669)
27. Vieta E, Herraiz M, Fernàndez A et al. Efficacy and safety in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. J Clin Psychiatry 2001 62 : 623 630. (Pubitemid 32848167)
28. Mohl A, Westlye K, Opjordsmoen S et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychomarmacol 2005 19 (suppl. 1 22 31.
29. Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996 153 : 759 764.
30. Ciapparelli A, Dell'osso L, Pini S, Chiavacci MC, Fenzi M, Cassano G. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000 61 : 329 334.
31. Ciapparelli A, Dell'osso L, Bandettini Di Poggio A et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003 64 : 451 458.
32. Zarate CA, Narendran R, Tohen M et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998 59 : 24 28.
33. Zarate CA, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000 61 : 185 189.
34. Mcelroy SL, Dessain EC, Pope HG et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991 52 : 411 414.
35. Keck P Jr., Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998 140 : 173 184.
36. Daniel D, Zimbroff DL, Potkin SG, and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999 20 : 491 505.
37. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomized study. Eur Arch Psychiatry Clin Neurosci 1997 247 : 42 50. (Pubitemid 27113062)
38. Maj M. Lithium prophylaxis of schizoaffective disorders: a prospective study. J Affect Disord 1988 14 : 129 135.
39. Minnai GP, Tundo A. Effects of lithium on the course and symptoms of schizo-affective disorder. Lithium 1990 1 : 191 193.
40. Baethge C, Gruschka P, Berghöfer A et al. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 2004 79 : 43 50.
41. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuro-Psychopharmacol 1981 5 : 507 510.
42. Chengappa K, Kupfer DJ, Parepally H et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 2007 9 : 609 617.
43. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Psychopharmacol 2003 23 : 223 228.
44. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981 42 : 124 128.
45. Biederman J, Lerner Y, Belmaker R. Combination of lithium carbonate and haloperidol in schizo-affective disorder. Arch Gen Psychiatry 1979 36 : 327 333.
46. Kramer MS, Vogel WH, Dijohnson C et al. Antidepressants in "depressed" schizophrenic inpatients. Arch Gen Psychiatry 1998 46 : 922 928.
47. Müller-Siecheneder F, Müller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998 18 : 111 120.
48. Grossman LS, Harrow M, Goldberg JF, Fichtner CG. Outcome of schizoaffective disorder at two long-term follow-ups: comparison with outcome of schizophrenia and affective disorders. Am J Psychiatry 1991 148 : 1359 1365.
49. Keck P Jr., Wilson DR, Strakowski SM et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorder. J Clin Psychiatry 1995 56 : 466 470.
50. Flynn J, Grieger TA, Benedek DM. Pharmacological treatment of hospitalized patients with schizoaffective disorder. Psychiatr Serv 2002 53 : 94 96.
51. Swoboda E, Conca A, König P, Waanders R, Hansen M. Maintenance electroconvulsive therapy in affective and schizoaffective disorder. Neuropsychobiology 2001 43 : 23 28.
52. Bauer M, Berghöfer A, Bschor T et al. Supraphysiological doses of l-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002 27 : 620 628.
53. Mcelroy SL, Keck JRPE, Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry 1999 60 (suppl. 5 16 21.
54. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999 156 : 1138 1148.
55. Baethge C. Long-term treatment of schizoaffective disorder. Review and recommendations. Pharmacopsychiatry 2003 36 : 45 56.
56. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005 39 : 1 30.
57. Marneros A. Schizophrenie-ähnliche Störungen und nichtorganische Wahnerkrankungen. In : Möller HJ, Laux G, Kapfhammer HP, eds. Psychiatrie und Psychotherapie, 3rd edn. Berlin : Springer, 2008 : 357 390.
58. Mensink GJR, Slooff CL. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand 2004 109 : 405 419.
59. Leucht S, Mcgrath J, Kissling W. Lithium for schizophrenia. Cochrane Database Syst Rev 2007 CD003834.
60. Leucht S, Mcgrath J, Kissling W, White P. Carbamazepin for schizophrenia. Cochrane Database Syst Rev 2007 CD001258.
61. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004 CD:004028.
62. Jäger M, Bottlender R, Strauss A, Möller HJ. Classification of functional psychoses and its implication for prognosis. Comparison between ICD-10 and DSM-IV. Psychopathology 2004 37 : 110 117.
63. Tollefson DG, Baesley CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders. Results of an international collaborative trial. Am J Psychiatry 1997 154 : 457 465.
64. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008 371 : 1048 1049.
65. Zimbroff D, Warrington L, Loebel A, Yang R, Sui C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007 22 : 363 370.
66. Perlis RH, Welge JA, Bornik LA et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006 67 : 509 516.
67. Thase ME, Macfadden E, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006 26 : 600 609.
68. Zaudig M, Stieglitz RD, Gastpar M, Rosinger C. Mood (affective) and schizoaffective disorders (section F3): results of the ICD-10 field trial. Pharmacopsychiatry 1990 23 (suppl. 4 160 164.
69. Sartorius N, Kaelber CT, Cooper JE et al. Progress toward achieving a common language in psychiatry. Results from the field trial of the clinical guidelines accompanying the WHO classification of mental and behavioural disorders in ICD-10. Arch Gen Psychiatry 1993 50 : 115 124.
70. Hiller W, Dichtl G, Hecht H, Hundt W, Von Zerssen D. An empirical comparison of diagnosis and reliabilities in ICD-10 and DSM-III-R. Eur Arch Psychiatry Clin Neurosc 1993 242 : 209 217.
71. Sartorius N, Üstüm TB, Korten A, Cooper JE, Van Drimmelem J. Progress toward achieving a common language in psychiatry, II: results from the international field trials of ICD-10 diagnostic criteria for research for mental and behavioural disorders. Am J Psychiatry 1995 152 : 1427 1431.
72. Maj M, Pirozzi R, Formicola AM, Bartoli l, Bucci P. Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord 2000 57 : 95 98.
73. Meyer F, Meyer T. The misdiagnosis of bipolar disorder as a psychotic disorder: some of its causes and their influence on therapy. J Affect Disord 2009 112 : 174 183.
74. Kendell RE. The role of diagnosis in psychiatry. Oxford : Blackwell Scientific Publications, 1975.
75. Kendell RE, Gourlay J. The clinical distinction between the affective psychoses and schizophrenia. Br J Psychiatry 1970 117 : 261 266.
76. Brockington IF, Kendell RE, Winwright S, Hiller VF, Walker J. The distinction between affective psychoses and schizophrenia. Br J Psychiatry 1979 135 : 243 248.
77. Jablensky A, Woodbury MA. Dementia praecox and manic-depressive insanity in 1908: a grade of membership analysis of the Kraepelinian dichotomy. Eur Arch Psychiatry Clin Neurosci 1995 245 : 202 209.
78. Angst J, Scharfetter C, Stassen HH. Classification of schizo-affective patients by multidimensional scaling and cluster analysis. Psychiatr Clin 1983 16 : 254 264.
79. Torrent C, Martínez-Aràn A, Amann B et al. Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr Scand 2007 116 : 453 460.
80. Peralta V, Cuesta MJ. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. J Affect Disord 2008 108 : 71 86.
81. Laursen TM, Labouriau R, Licht RW, Bertelsen A, Munk-Olsen T, Mortensen PB. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry 2005 62 : 841 848.
82. Maier W, Lichtermann D, Franke P, Heun R, Falkai P, Rietschel M. The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophr Res 2002 57 : 259 266.
83. Hamshere ML, Bennett P, Williams N et al. Genomewide linkage scan in schizoaffective disorder. Significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry 2005 62 : 1081 1088.
84. Hodgkinson CA, Goldman D, Jaeger J. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004 75 : 862 872.
85. Allardyce J, Gaebel W, Zielaseck J, Van Os J. Deconstructing Psychosis Conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis. Schizophr Bull 2007 33 : 863 867.
86. Gaebel W, Zielaseck J. The DSM-V initiative "deconstructing psychosis" in the context of Kraepelin's concept on nosology. Eur Arch Psychiatry Clin Neurosci 2008 258 (suppl. 2 41 47.
87. Möller HJ. Systematic of psychiatric disorders between categorical and dimensional approaches. Eur Arch Psychiatry Clin Neurosci 2008 258 (suppl. 2 48 73.
88. Malhi GS, Green M, Fagiollini S, Peselow ED, Kumari V. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord 2008 10 : 215 230.
89. Craddock N, Owen MJ. The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 2005 186 : 364 366.
90. Mackinejad K, Sharifi V. Wittgenstein's philosophy and a dimensional approach to the classification of mental disorders - a preliminary scheme. Psychopathology 2006 39 : 126 129.
91. Lake CR, Hurwitz N. Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease - there is no schizoaffective disorder. Curr Opin Psychiatry 2007 20 : 365 379.